FGFR-driven urothelial cancer

1 Dataset 2 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001011063	We performed a global mutational landscape analysis using tumor samples from the 47 urothelial cancer patients included in MATCH-R or MOSCATO studies, with advanced metastatic disease and WES available (RNAseq is included for 38 patient samples).	Illumina HiSeq 2000 Illumina HiSeq 4000 Illumina NovaSeq 6000 NextSeq 500	133

Publications	Citations
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez Arango JD, Guaitoli G, Mizuta H, Combarel D, Tselikas L, Michiels S, Nikolaev SI, Scoazec JY, Ponce-Aix S, Besse B, Olaussen KA, Loriot Y, Friboulet L. Cancer Discov 13: 2023 1998-2011	44
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer. Zhao H, Gao X, Jiang Y, Yu Y, Wang L, Sun J, Wang M, Xiong X, Huang C, Zhang H, Jiang G. Adv Sci (Weinh) 12: 2025 e2413209	3